[MO44] Mini-Oral Session 44　Lung Cancer / Thoracic Cancer 7（ICI）
【E】

[MO44-4] Phase II study of Nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616L

^○Satoru Miura¹, Hiroaki Akamatsu², Shunsuke Teraoka², Shinkichi Takamori³, Hidetoshi Hayashi⁴, Akito Hata⁵, Yukihiro Toi⁶, Yoshimasa Shiraishi⁷, Nobuaki Mamesaya⁸, Yuki Sato⁹, Naoki Furuya¹⁰, Yasuhiro Koh², Toshihiro Misumi¹¹, Nobuyuki Yamamoto², Kazuhiko Nakagawa⁴ (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.Internal Medicine III, Wakayama Medical University, 3.Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 4.Department of Medical Oncology, Kindai University Faculty of Medicine, 5.Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, 6.Department of Pulmonary Medicine, Sendai Kousei Hospital, 7.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 8.Department of Thoracic Oncology, Shizuoka Cancer Center, 9.Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 10.Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, 11.Department of Biostatistics, Yokohama City University Graduate School of Medicine)